Generally speaking, our findings suggested the decline of released IL1B accounted for impaired EMT phenotype, and growth inhibition, and supplement with IL1B could rescue the defects in HCC progression in CD44s deficient cells. Here, IL1B is linked to hepatocellular carcinoma.